| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1070242 | Drug and Alcohol Dependence | 2011 | 7 Pages |
Abstract
The present results demonstrate that methamphetamine use during alprazolam XR treatment would not pose a significant safety risk. Given the potential of GABAA positive modulators to manage certain aspects of stimulant abuse and dependence (i.e., drug-induced seizures, anxiety and stress), but the relatively small impact on the acute abuse-related effects of methamphetamine observed here, additional research with GABAA positive modulators is warranted, but should consider their use as an adjunct component of combination behavioral and/or drug treatment.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Joshua A. Lile, William W. Stoops, Paul E.A. Glaser, Lon R. Hays, Craig R. Rush,